Skip Navigation



NDT Advance Access published online on November 24, 2006

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl634
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/3/880    most recent
gfl634v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tostivint, I.
Right arrow Articles by Isnard Bagnis, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tostivint, I.
Right arrow Articles by Isnard Bagnis, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Renal outcome after ciclosporin-induced nephrotoxicity

Isabelle Tostivint1, Sophie Tezenas du Montcel2, Marie Chantal Jaudon4, Alain Mallet2, Phuc Le Hoang3, Bahram Bodaghi3, Gilbert Deray1 and Corinne Isnard Bagnis1

1Department of Nephrology, Pitié Salpétrière Hospital, 2Department of Biostatistics and Medical Information, Pitié Salpétrière Medical University, 3Department of Ophtalmology, and 4Department of Biochemistry, Pitié Salpétrière Hospital, Paris, France

Correspondence and offprint requests to: Correspondence and offprint request to: Dr Isabelle Tostivint, Service de Néphrologie, Hôpital Pitié Salpétrière, 83 Boulevard de l’Hôpital, 75013 Paris, France. Email: isabelle.tostivint{at}psl.aphp.fr



  Abstract

Background. Renal outcome after ciclosporin (CsA) is not clear in most studies involving patients with many renal comorbid conditions. We first report on renal function recovery after CsA in previously healthy kidney patients.

Methods. Uveitis patients, enroled in a unique single centre cohort follow-up study initiated in 1987, were prospectively evaluated for plasma creatinine and glomerular filtration rate (GFR) before, during (>2 years) and after (>6 months) CsA therapy. We hypothesized that CsA alters renal function progressively over time according to two additive exponential components (irreversible and reversible) and used a mixed linear model with exponential speed parameters maximizing the likelihood.

Results. Twenty-seven patients treated for 60±34 months (CsA 5.1±2.5 mg/kg/day) were followed up for 56±42 months after CsA withdrawal. Baseline creatinine was 0.92±0.15 mg/dl. The reversible effect of CsA was quantified as a 0.11±0.07 mg/dl increase in creatinine/100 mg CsA/day (P<0.001) and a 6.0±3.7 ml/min/1.73 m2 decrease in GFR/100 mg CsA/day (P<0.0001). The irreversible effect was quantified as a 0.03±0.05 mg/dl increase in creatinine/100 g cumulative CsA received (P<0.007) and a decrease of 3.3±3.9 ml/min/1.73 m2 GFR/100 g CsA.

Conclusions. Although significant decrease in GFR is induced by low-dose CsA therapy in previously healthy kidney patients, renal function recovery is possible after CsA withdrawal and best predicted by CsA daily dosage. Irreversible loss in GFR is correlated to cumulated CsA exposure. The lowest CsA dosage and shortest exposure time effect as well as unlimited renal monitoring are required in order to provide the best long-term renal outcome.

Keywords: ciclosporin; glomerular filtration rate; hypertension; nephrotoxicity; reversibility; uveitis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.